Pantera NV
Latest round
- Series A
Last raised
- Sep 2024
Total raised
- $70M
Investors
- 7
About Pantera NV
Founded in 2022 and based in Belgium, PanTera NV engages in the production of actinium-225 for targeted cancer therapy. As of 2024, the company is headed by its CEO Sven Van Den Berghe. PanTera focuses on the large-scale production of radiopharmaceuticals. It produces an Ac-225 which is an alpha-emitting radioisotope that helps fight cancers through Targeted Radio Therapy (TRT). This approach enables precise delivery of therapeutic radiation to tumors, minimizing damage to surrounding healthy tissue.
Who invested in Pantera NV
7 investors across 1 round
See all investors in Pantera NV
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Sep 18, 2024
Amount
$70M
Investors
Questions about Pantera NV
Who invested in Pantera NV?
Pantera NV has 7 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Pantera NV raised?
Pantera NV has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Pantera NV last raise money?
Pantera NV's most recent round on record is a Series A, in Sep 2024.
What does Pantera NV do?
Founded in 2022 and based in Belgium, PanTera NV engages in the production of actinium-225 for targeted cancer therapy.
Where is Pantera NV headquartered?
Pantera NV is headquartered in Belgium.
Which VCs invest in companies like Pantera NV?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back pharmaceuticals companies at Pantera NV's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Pantera NV? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.